Showing results (151-160 of 340) with videos related to
Sort By:
Pageof 34
Plos One|October 8, 2015
The Role of Patients' Age on Their Preferences for Choosing Additional Blood Pressure-Lowering Drugs: A Discrete Choice Experiment in Patients with DiabetesSieta T de Vries, Folgerdiena M de Vries, Thijs Dekker, et al.Journal of Drug Targeting|May 9, 2002
Targeting of doxorubicin to the urinary bladder of the rat shows increased cytotoxicity in the bladder urine combined with an absence of renal toxicityMarijke Haas, Frits Moolenaar, Angela Elsinga, et al.British Journal of Pharmacology|August 7, 2002
Renal targeting of captopril selectively enhances the intrarenal over the systemic effects of ACE inhibition in ratsR Folgert G Haverdings, Marijke Haas, Gerjan Navis, et al.Kidney International|February 19, 2002
Addition of AT1 blocker fails to overcome resistance to ACE inhibition in adriamycin nephrosisHendrik Bos, Robert H Henning, Eric De Boer, et al.Journal of the American Society of Nephrology : JASN|May 16, 2009
High protein intake associates with cardiovascular events but not with loss of renal functionNynke Halbesma, Stephan J L Bakker, Desiree F Jansen, et al.Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 30, 2008
Renal endothelial function and blood flow predict the individual susceptibility to adriamycin-induced renal damagePeter Ochodnicky, Robert H Henning, Hendrik Buikema, et al.Journal of the Renin-Angiotensin-Aldosterone System : JRAAS|June 14, 2003
Involvement of renal ACE activity in proteinuria-associated renal damage in untreated and treated adriamycin nephrotic ratsHendrik Bos, Gozewijn D Laverman, Robert H Henning, et al.American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 3, 2014
GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug AdministrationAndrew S Levey, Lesley A Inker, Kunihiro Matsushita, et al.Journal of the American Society of Nephrology : JASN|December 8, 2004
Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial resultsGiuseppe Remuzzi, Piero Ruggenenti, Annalisa Perna, et al.Diabetes, Obesity & Metabolism|March 18, 2024
Aldosterone synthase inhibitor (BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: A multicentre, randomized, double-blind, placebo-controlled, Phase I trialStefan R Bornstein, Dick de Zeeuw, Hiddo J L Heerspink, et al.Pageof 34